Downregulation of the HIF2a target cyclin D1 underlies the efficacy of the HIF2a inhibitor belzutifan in kidney cancer.

Shirole, NH; Kesar, D; Sellers, WR; Kaelin, WG

CANCER RESEARCH, 2023; 83 (16):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索